Hi, what are you looking for?
The US Food and Drug Administration gave its seal of approval to a generic version of injectable lenacapavir, the drug that can protect from...
Tuberculosis (TB) is responsible for about a quarter of all AIDS deaths. In 2024, it was also the leading cause of death among people...
A new approach replaces rilpivirine with lenacapavir, a long-acting drug that attacks HIV in a different way.
Injections were found to be more effective at keeping the virus suppressed than the tablets, so efforts should be made to make this treatment...
Long-acting HIV therapies are becoming an increasingly competitive treatment category. While efficacy remains essential, differentiation is now shifting towards factors such as dosing convenience,...
A one-time regimen of therapies given to newborns within three days of birth may permanently clear the virus.